KTH-222

KTH-222 is a novel, synthetic peptide composed of 8 amino acids, derived from a motif found in the atrial natriuretic peptide (ANP) family and related peptides. It has demonstrated potent anti-tumor activity in preclinical models, particularly against human pancreatic cancer. Mechanistically, KTH-222 inhibits tubulin polymerization and disrupts microtubule formation, which impairs cancer cell attachment, proliferation, and invasive morphology. Additionally, it regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. In mouse xenograft models of pancreatic cancer (MIA PaCa-2), KTH-222 was more effective than gemcitabine at reducing tumor growth and prolonging survival with minimal toxicity observed. The drug is being developed as both monotherapy and in combination with other agents for enhanced efficacy and reduced toxicity[2][3][5][6][9].